Drug Trial Radar · NCT06121830
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)
Last checked: Nov 19, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
324
Planned (sponsor's estimate)
Start
Aug 31, 2023
Primary completion
Jan 2025
Study completion Mar 2025
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to determine the efficacy and safety of DWP14012 compared to a placebo following a once-daily oral dose of DWP14012 at 20 mg, 40 mg, or placebo for 4 weeks in patients with NERD.
Conditions
- Non-erosive Reflux Disease
- Non-Erosive Gastro-Esophageal Reflux Disease
- Non-Erosive Esophageal Reflux Disease
Interventions
DWP14012 20mgDrug
DWP14012 20mg, tablet, orally, once daily for up to 4 weeks
DWP14012 40mgDrug
DWP14012 40mg, tablet, orally, once daily for up to 4 weeks
PlaceboDrug
Placebo, tablet, orally, once daily for up to 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of heartburn-free days for 4 weeks (daytime/nighttime)Time frame: 4 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wonkwang University Hospital
Iksan, Jeollabuk-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.